ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 13 Sep 2024
Last Updated on 13 Sep 2024
A- A+
Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has not recommended cabotegravir with rilpivirine for inclusion on the MOH List of Subsidised Drugs for treating Human Immunodeficiency Virus type 1 (HIV-1) infection. The decision was based on the unfavourable cost-effectiveness of cabotegravir with rilpivirine at the price proposed by the company compared with subsidised oral antiretroviral therapies.


Cabotegravir with rilpivirine for treating Human Immunodeficiency Virus type 1 infection (Published 13 Sep 2024) PES Cabotegravir with rilpivirine for treating Human Immunodeficiency Virus type 1 (HIV-1) infection (Published 13 Sep 2024)